Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDS-PLAN: Molecular Guided Therapy and DFMO for High-Risk Neuroblastoma
NCT02559778Phase 2Recruiting
- Start
- Sep 2015
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of eflornithine in neuroblastoma, ganglioneuroblastoma (GNB). Started Sep 2015; status: recruiting.
02
Drugs
eflornithine
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT02559778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559778.